TriLink BioTechnologies
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, nucleoside triphosphates and mRNA capping analogs. They has scale-up expertise and unique mRNA, oligonucleotide and plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.
Latest TriLink BioTechnologies Content
Poster
Revolutionize mRNA Manufacturing Using a Novel RNA Polymerase
This poster explores how a novel polymerase variant provides the tools needed to reduce double-stranded RNA (dsRNA) byproducts during manufacturing, ensuring the tolerability, safety and potency of mRNA vaccines and therapeutics.
Whitepaper
The Economics of Synthetic mRNA Capping Strategies
This whitepaper evaluates the results of a study into the three main capping options available to manufacturers, highlighting expert insights on mRNA capping costs and customer needs.
Product News
TriLink BioTechnologies Collaborates With Johns Hopkins University To Establish a New RNA Innovation Center
The collaborative center will help to lower barriers to RNA innovation and discovery.
Product News
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) has announced the grand opening of its new cGMP mRNA manufacturing facility.
Product News
TriLink BioTechnologies® Solidifies IP Position With Awarded Patents for CleanCap® Capping Technology in China and Canada
TriLink’s CleanCap® capping technology is patented globally & TriLink is the sole authorized manufacturer of CleanCap® capping analogs
Article
Next-Gen mRNA Technology: A Crucial Pandemic Preparedness Tool
Drew Burch discusses how next-gen mRNA technology is one of the most valuable tools to combat and control disease outbreaks and why continued investment in this field is crucial for maintaining our pandemic preparedness.
Product News
TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion As mRNA Manufacturing Facility Nears Completion
TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials.
Advertisement
